ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Phase 4

Terminated

• Conditions: Atherosclerosis; HIV
• Interventions: Drug: niacin/laropiprant; Drug: Placebo

• Registration Number: NCT01683656
• Lead Sponsor: Calmy Alexandra

Brief Summary

HIV-infected patients are at increased risk for cardiovascular disease. Large investigations support an inverse correlation between HDL-C levels and coronary heart disease. Therefore a treatment lowering HDL-C such as niacin could reduce the risk of atheroprogression not only through its benefit in terms of lipid profile, but also by reducing atherosclerotic inflammation.

The study aims at showing that a therapy targeting HDL-C increase in HIV-infected patients on suppressive cART has the potential for reducing subclinical atherosclerotic inflammation associated with HIV itself in HIV-individuals on cART.

NILACH is a randomised, multicenter, double blind, placebo controlled, 48 weeks trial to test the effect of the newly marketed niacin/laropiprant on carotid intima-media thickness (IMT) in 90 subjects.

* Regimen 1: ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study (the titration aims to reduce adverse reactions)

* Regimen 2: ER niacin/laropiprant placebo p.m.

The primary end point is the change in mean common carotid intima-media thickness from baseline and 48 weeks, compared between the niacin/laropiprant group and the placebo group.

The proposed in vivo experiments should provide insights on the potential benefits of niacin treatment of cardiovascular disease in HIV patients. In addition, we will be able to further clarify the role of systemic inflammatory mediators in the development of early atherosclerosis of HIV-infected patients on antiretroviral therapy. Detection and treatment of non-infectious co-morbidities such as cardiovascular diseases have become essential for HIV-infected individuals exposed to lifelong antiretroviral therapy and go beyond mere management of opportunistic infections or virologic suppression.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-08
• Study First Submitted: 2012-08-31
• Study First Submitted QC: 2012-09-07
• Study First Posted: 2012-09-12
• Primary Completion: 2014-07
• Study Completion: 2014-07
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-07
• Last Update Posted: 2019-10-08

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Adult patients > 40 years;
• Women of childbearing potential must use two reliable contraceptive methods during the entire trial, from day 1 to one month after the end of the trial.
• Signing the study consent form;
• Stable cART since at least 3 months (ie no recent drug change);
• HIV-RNA below 100 copies for at least 6 months;
• HDL-cholesterol <1.29 mmol/l for men; <1.42 mmol/l for women

Exclusion Criteria

• Pregnancy or lactation;

• Congestive Heart Failure;

• Malignant Hypertension;

• Acute or chronic coronary artery diseases;

• Any known cardiac arrhythmias;

• Diabetes;

• Concomitant cancer, rheumatologic disease or inflammatory bowel diseases;

• Concomitant renal or hepatic disease:

  • Creatinine above 150 micromol/L
  • Transaminases above 5 times upper normal limit
  • Prothrombin time (Quick) value below 50%;

• Prior intolerance to niacin therapy (reported in a medical report);

• Cyclosporine, anti-inflammatory drugs (other than aspirin) or cytokine therapy in concomitant intake;

• Abnormal thyroid function;

• Excessive consumption of alcohol;

• Known severe lactose intolerance.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ER Niacin/laropipant	niacin/laropiprant	ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
ER Niacin/laropipant Placebo	Placebo	ER niacin/laropiprant placebo p.m.

Primary Outcome Measures

Name	Time	Method
change in mean common carotid intima-media thickness	48 weeks	mean of maximal IMT value will be calculated over three cardiac cycles and for left and right carotid artery at baseline and week 48. The primary endpoint will be assessed by a single investigator in a blinded and anonymized fashion at cIMT Core Facility, Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada Responsible: Pr Jean-Claude Tardif.

Secondary Outcome Measures

Name	Time	Method
Clinical MACE: cardiovascular mortality, stroke, acute coronary syndromes, any cardiac arrhythmias, hospitalisation for cardiovascular causes, peripheral artery disease, revascularization.	one year
Mean Total Cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, apolipoprotein, triglycerides, and apolipoprotein (apo) Al, B and E levels	12, 24, 48 weeks
Mean biomarkers of inflammatory process (fibrinogen, S-VCAM-1, adiponectin, CCL2, CCL3, d-dimer, IL-6, TNF-alpha, Lp-PLA2) changes	12, 24, 48 weeks
Mean hs-CRP plasma concentration changes	12, 24, 48 weeks

Trial Locations

Locations (7)

University Hospitals Genève; 🇨🇭 Geneva, GE, Switzerland

Kantonsspital St Gallen; 🇨🇭 St Gallen, SG, Switzerland

University Hospital Zurich; 🇨🇭 Zurich, ZH, Switzerland

University Hospital Berne Inselspital; 🇨🇭 Berne, BE, Switzerland

EOC Ente Ospedaliero Cantonale, civico; 🇨🇭 Lugano, TI, Switzerland

University Hospital Basel; 🇨🇭 Basel, BS, Switzerland

CHUV Cantonal University Hospital Vaud; 🇨🇭 Lausanne, VD, Switzerland